*Trabecular meshwork (trabeculotomy), Schlemm's canal (canaloplasty), and collector channels (canaloplasty).
1
Klabe K, et al. 2021 Jul 20. Clin Ophthalmol. 15:3121-3129.
INDICATIONS FOR USE: The OMNI
®
Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal)
followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.
CONTRAINDICATIONS: Do not use the OMNI Surgical System in any situations where the iridocorneal angle is compromised or has been damaged (e.g., from
trauma or surgery), since it may not be possible to visualize the angle or to properly pass the microcatheter. Do not use the OMNI Surgical System in patients with
angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris.
Do not use the OMNI Surgical System in quadrants with previous MIGS implants. Please refer to the full Instructions For Use, available at omnisurgical.com/IFU,
for warnings, precautions, and adverse event information.
©2023 Sight Sciences, Inc. OMNI is a registered trademark of Sight Sciences, Inc. 01/2023 OM-2514-US.v2
The OMNI
®
Surgical System from Sight Sciences is the
first and only glaucoma device indicated for canaloplasty
followed by trabeculotomy that allows you to:
PERFORM
Two implant-free procedures
in both standalone MIGS
and combo cataract
TARGET
Three points of resistance
intended to lower IOP*
DELIVER
Sustained long-term
IOP reduction
1
RELY
On an established
reimbursement code
ONLY
OMNI CAN
Visit OMNIsurgical.com to discover the benefits
Ergo-Series now available in the United States.
Scan to schedule a demo.
